年轻起病结直肠腺瘤患者异时性进展期肿瘤的患病率、危险因素及风险的系统综述
该系统综述检索多个电子数据库至2019年2月12日,纳入18至49岁人群研究。年轻起病腺瘤(YOA)合并患病率为9.0%(95%CI 7.1%-11.4%),尸检研究为3.9%(95%CI 1.9%-7.6%),结肠镜研究为10.7%(95%CI 8.5%-13.5%)。基线YOA诊断后异时性进展期肿瘤合并发生率为6.0%(95%CI 4.1%-8.6%),仅报告1例结直肠癌。
要点
- 年轻起病腺瘤合并患病率为9.0%(95%CI 7.1%-11.4%),结肠镜研究为10.7%(95%CI 8.5%-13.5%)。
- 仅年龄增长被确定为YOA的一致危险因素,基于4项研究共78,880人。
- YOA诊断后异时性进展期肿瘤合并发生率为6.0%(95%CI 4.1%-8.6%),仅1例结直肠癌。
核心结论
- 该系统综述估计年轻起病腺瘤患病率为9%,且随年龄增长而增加;YOA诊断后异时性进展期肿瘤风险估计为6%。
- 需要更多研究来了解与YOA相关的患病率、危险因素和结直肠癌风险。
研究设计与样本
- 系统综述,检索多个电子数据库至2019年2月12日,纳入报告18至49岁人群腺瘤患病率、腺瘤危险因素和/或异时性进展期肿瘤风险的研究。
- 在可行时采用随机效应Meta分析得出汇总估计值。
主要发现
- YOA总体合并患病率为9.0%(95%CI 7.1%-11.4%),基于24项研究共23,142人。
- 亚组分析中,尸检研究的YOA合并患病率为3.9%(95%CI 1.9%-7.6%),结肠镜研究的患病率为10.7%(95%CI 8.5%-13.5%)。
- 仅年龄增长被确定为YOA的一致危险因素,基于4项研究共78,880人。
- 基线YOA诊断后异时性进展期肿瘤的合并发生率为6.0%(95%CI 4.1%-8.6%),基于3项研究共1,493名接受随访结肠镜检查者,仅报告1例结直肠癌。
- 总体而言,报告异时性进展期肿瘤的研究很少,且无研究评估常规监测结肠镜检查是否降低结直肠癌风险。
局限性
- 报告异时性进展期肿瘤的研究很少。
- 无研究评估常规监测结肠镜检查是否降低结直肠癌风险。
- 需要更多研究来了解与YOA相关的患病率、危险因素和结直肠癌风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The incidence and mortality of early-onset colorectal cancer (CRC) are increasing. Adenoma detection, removal, and subsequent endoscopic surveillance might modify risk of CRC diagnosed before age 50 years (early-onset CRC). We conducted a systematic review of young-onset adenoma (YOA) prevalence, associated risk factors, and rate of metachronous advanced neoplasia after YOA diagnosis. METHODS: We performed a systematic search of multiple electronic databases through February 12, 2019 and identified studies of individuals 18 to 49 years old that reported prevalence of adenoma, risk factors for adenoma, and/or risk for metachronous advanced neoplasia. Summary estimates were derived using random effects meta-analysis, when feasible. RESULTS: The pooled overall prevalence of YOA was 9.0% (95% CI, 7.1%-11.4%), based on 24 studies comprising 23,142 individuals. On subgroup analysis, the pooled prevalence of YOA from autopsy studies was 3.9% (95% CI, 1.9%-7.6%), whereas the prevalence from colonoscopy studies was 10.7% (95% CI, 8.5%-13.5). Only advancing age was identified as a consistent risk factor for YOA, based on 4 studies comprising 78,880 individuals. Pooled rate of metachronous advanced neoplasia after baseline YOA diagnosis was 6.0% (95% CI, 4.1%-8.6%), based on 3 studies comprising 1493 individuals undergoing follow-up colonoscopy, with only 1 CRC case reported. Overall, few studies reported metachronous advanced neoplasia and no studies evaluated whether routine surveillance colonoscopy decreases risk of CRC. CONCLUSIONS: In a systematic review, we estimated the prevalence of YOA to be 9% and to increase with age. Risk for metachronous advanced neoplasia after YOA diagnosis is estimated to be 6%. More research is needed to understand the prevalence, risk factors, and risk of CRC associated with YOA.
引用
- Enwerem N, Cho MY, Demb J, et al. Systematic Review of Prevalence, Risk Factors, and Risk for Metachronous Advanced Neoplasia in Patients With Young-Onset Colorectal Adenoma. Clin Gastroenterol Hepatol. 2020. PMID: 32428708. doi:10.1016/j.cgh.2020.04.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。